Perspective Therapeutics (NYSEAMERICAN:CATX) Raised to Strong-Buy at BMO Capital Markets

Perspective Therapeutics (NYSEAMERICAN:CATX) was upgraded by research analysts at BMO Capital Markets to a “strong-buy” rating in a research report issued on Tuesday,Zacks.com reports.

CATX has been the topic of a number of other research reports. BTIG Research reaffirmed a “buy” rating on shares of Perspective Therapeutics in a research report on Friday, July 24th. Wedbush reissued an “outperform” rating and set a $11.00 price objective on shares of Perspective Therapeutics in a research report on Tuesday, May 5th. Bank of America cut their target price on shares of Perspective Therapeutics from $6.00 to $5.00 and set a “neutral” rating on the stock in a research note on Friday, August 14th. Finally, Piper Sandler reduced their target price on shares of Perspective Therapeutics from $16.00 to $14.00 and set an “overweight” rating on the stock in a report on Tuesday, August 11th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $11.50.

Perspective Therapeutics Price Performance

Shares of CATX stock opened at $3.48 on Tuesday. The firm has a 50 day moving average of $3.10 and a two-hundred day moving average of $3.95. Perspective Therapeutics has a 52 week low of $1.96 and a 52 week high of $6.16.

Perspective Therapeutics (NYSEAMERICAN:CATX) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.03. The business had revenue of $0.08 million for the quarter, compared to analyst estimates of $0.09 million. Perspective Therapeutics had a negative return on equity of 41.92% and a negative net margin of 28,467.97%. As a group, analysts anticipate that Perspective Therapeutics will post -1.03 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the business. Commodore Capital LP purchased a new stake in Perspective Therapeutics during the first quarter worth approximately $26,424,000. Affinity Asset Advisors LLC increased its stake in Perspective Therapeutics by 954.9% in the first quarter. Affinity Asset Advisors LLC now owns 3,164,582 shares of the company’s stock valued at $13,196,000 after purchasing an additional 2,864,582 shares during the last quarter. Avidity Partners Management LP increased its stake in Perspective Therapeutics by 88.4% in the first quarter. Avidity Partners Management LP now owns 6,049,999 shares of the company’s stock valued at $25,228,000 after purchasing an additional 2,839,266 shares during the last quarter. Spruce Street Capital LP acquired a new stake in Perspective Therapeutics during the first quarter worth approximately $10,955,000. Finally, Opaleye Management Inc. acquired a new stake in Perspective Therapeutics during the fourth quarter worth approximately $3,257,000. 54.66% of the stock is owned by institutional investors and hedge funds.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.